CA
BPMC

Calton & Associates’s Blueprint Medicines BPMC Stock Holding History

Calton & Associates’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,423
Closed -$224K – 200
2023
Q4 		$224K Buy
+2,423
New +$157K 0.09% 216
2021
Q1 		– Sell
-2,019
Closed -$226K – 405
2020
Q4 		$226K Buy
+2,019
New +$213K 0.04% 340

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Calton & Associates's BPMC Position: Q1 2024 in Review

Calton & Associates sold out of Blueprint Medicines (BPMC) in Q1 2024, closing a stake of 2,423 shares — an estimated $224K sold.

Calton & Associates first reported a position in BPMC in Q4 2020 and held it in 2 quarters. The position peaked at $226K in Q4 2020. 283 funds tracked by Wall St. Rank hold BPMC as of Q1 2024.

  • Calton & Associates reported no remaining Blueprint Medicines position as of Q1 2024 after selling out during the quarter.
  • Calton & Associates sold 2,423 Blueprint Medicines shares in Q1 2024, an estimated $224K.
  • Calton & Associates first reported a position in Blueprint Medicines in Q4 2020 and held it in 2 quarters.
  • Calton & Associates's Blueprint Medicines position peaked at $226K in Q4 2020.
  • 283 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2024.

Based on Calton & Associates's 13F filing for Q1 2024, filed 16 Apr 2024.